Regeneron Pharmaceuticals shares are trading lower after the FDA declined to approve a higher-dose version of EYLEA.
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals' shares are trading lower after the FDA declined to approve a higher-dose version of EYLEA.
June 27, 2023 | 7:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals' stock price is expected to decrease in the short term due to the FDA's rejection of a higher-dose version of EYLEA.
The FDA's rejection of a higher-dose version of EYLEA is a setback for Regeneron Pharmaceuticals, which could negatively impact the company's revenue and profitability. This is likely to lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100